Menu
Back
24 July 2024
The ITA reports that a sample collected during a targeted out-of-competition test on 17 February 2024 from Tuğrulhan Erdemir has returned an Atypical Finding (ATF)1 for the prohibited substance “hydrochlorothiazide”.
Hydrochlorothiazide is prohibited under the 2024 WADA Prohibited list as a diuretic and masking agent (S.5). It is prohibited at all times (in-competition and out-of-competition).
In accordance with the WADA stakeholder notice regarding potential diuretic contamination cases (WADA Stakeholder Notice)2 the ITA initiated an investigation into whether the ATF was caused by inadvertent contamination from a pharmaceutical product taken by the athlete prior to sample collection.
The investigation concluded that there was no evidence that the ATF was caused by inadvertent contamination from a pharmaceutical product. In accordance with the WADA Stakeholder Notice, the ITA therefore pursued the ATF as an Adverse Analytical Finding (AAF)3 and charged the athlete with an anti-doping rule violation (ADRV) under Art. 2.1 of the International Boxing Association (IBA) Anti-Doping Rules (IBA ADR).
The ITA referred the case to the CAS ADD and imposed a provisional suspension on the athlete in accordance with Art. 7.4.2 of the IBA ADR. The athlete subsequently requested the lifting of the provisional suspension before the CAS ADD.
On 24 July 2024, and further to a fully-fledged hearing on the issue of the provisional suspension, CAS ADD issued an order confirming and maintaining the provisional suspension imposed on Tuğrulhan Erdemir which also extends to the Olympic Games Paris 2024.
The proceedings will now resume on the issue of the asserted ADRV and related consequences under the IBA ADR.
Pursuant to the IBA’s delegation of its anti-doping program to the ITA, the results management and prosecution of the case is being handled entirely by the ITA.
